ACIP Issues Recommendations for Seasonal Influenza Vaccine Use in 2022-23

The Advisory Committee on Immunization Practices (ACIP) has released its annual recommendations and reports for the use of seasonal influenza vaccines in the United States population during the 2022-23 influenza season. This publication provides updated guidance on vaccine selection, dosing, and administration schedules. The report is intended to inform clinical practice and public health policy for the upcoming season.

Specific study details, including study type, phase, sample size, and follow-up duration, are not reported, as this is a recommendations document rather than a primary research study. No primary or secondary outcomes, comparative data, or main results with exact numbers are presented. The publication focuses on providing authoritative guidance based on the committee's review of available evidence.

Safety and tolerability data for the vaccines are not reported within this specific recommendations document. Clinicians should refer to vaccine prescribing information and surveillance systems for adverse event profiles. Key limitations inherent to this type of publication include the absence of new primary data analysis and the reliance on previously reviewed evidence. The practice relevance is framed as updated guidance for immunization practice. Clinicians should implement these recommendations within the context of individual patient assessment and prevailing public health conditions.